R

Rocky Mountain Movement Disorders Center | Englewood, CO

Research site

(Unclaimed)

Location

701 East Hampden Avenue, Suite 510, Englewood, Colorado, United States of America

Site insights

Top conditions

Top treatments

Levodopa

ND0612

Carbidopa

ABBV-8E12

ENT-01

APL-130277

ABBV-951

Pf-02545920

PTC518

Isradipine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 29 total trials

A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease (BeyoND)

This is a multi-center, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa (LD/CD) delivered via a pump system as a...

Active, not recruiting

Parkinson's Disease

Drug: ND0612

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.

Active, not recruiting

Progressive Supranuclear Palsy

Drug: Placebo

Drug: TPN-101, 400 mg/day

A Study of Lu AF82422 in Participants With Multiple System Atrophy (AMULET)

To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.

Active, not recruiting

Multiple System Atrophy

Drug: Placebo

Drug: Lu AF82422

A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.

Active, not recruiting

Huntington Disease

Drug: Placebo

Drug: PTC518

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects wil...

Active, not recruiting

Parkinson's Disease

Drug: Placebo for Oral IR-LD/CD

Drug: Oral IR-LD/CD